COMMUNIQUÉS West-GlobeNewswire
-
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
02/12/2025 -
INVO Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
02/12/2025 -
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
02/12/2025 -
Precision Neuroscience Recognized for Innovation and Responsible Technology with Two Industry Awards
02/12/2025 -
Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions
02/12/2025 -
Tacalyx Appoints Jean Engela as Chief Executive Officer to Spearhead Next Phase of Growth
02/12/2025 -
The Ensign Group Grows Operations in Colorado
02/12/2025 -
The Ensign Group Increases Operations in Arizona
02/12/2025 -
The Ensign Group Adds Real Estate and Operations in Kansas
02/12/2025 -
Alberta Cancer Foundation launches 'The Time Store' campaign to bring more moments to Albertans facing cancer
02/12/2025 -
ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise
02/12/2025 -
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
02/12/2025 -
Hydreight Technologies Announces Corporate Update Highlighting Q3 Momentum, VSDHOne Acceleration, and 2026 Outlook
02/12/2025 -
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
02/12/2025 -
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
02/12/2025 -
Comanche Biopharma Appoints Richard Colvin, MD, PhD as Global Head of R&D and John McHutchison, AO, MD as Chairman and Director of Comanche Biopharma Australia
02/12/2025 -
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
02/12/2025 -
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
02/12/2025 -
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
02/12/2025
Pages